Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

SGN33A in Combo w/ Azacitidine in Pts w/ Prev Untreated IPSS Intermediate-2 Or High Risk MDS

Protocol: OSU-16169

Full Title

A Phase 1/2 of Vadastuximab Talirine (SGN-CD33A) in Combination with Azacitidine in pateints with previously untrated Intermediate International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome Leukemia